Hydrogel Prodrug Cross-Linking for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymer drug delivery systems face issues such as toxicity, non-biocompatibility, undesirable degradation by-products, initial burst release, and a disconnect between polymer degradation time and drug release period, leading to under- or over-dosing and high costs.
Innovation Solution
A hydrogel prodrug is developed by reacting drugs with acrylates to form polymer prodrugs, which are then cross-linked with a free radical initiator to create a backbone structure, allowing for controlled drug release through polymerization and cross-linking, ensuring biocompatibility and consistent drug levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional polymer drug delivery systems are used, then controlled drug release is achieved, but toxicity and non-biocompatibility issues occur
Solution Approach 1:
The patent changes the chemical parameters of the polymer system by using naturally occurring amino acids and sugars to form poly(β-amino ester) backbones, replacing synthetic polymers. This parameter change maintains controlled release capability while improving biocompatibility and reducing toxicity through natural, biodegradable materials.
Solution Approach 2:
The patent creates a composite structure where drug molecules are covalently bonded to the poly(β-amino ester) polymer backbone, forming an integrated prodrug system. This composite approach ensures the drug is released only through controlled polymer degradation, simultaneously achieving reliable controlled release and biocompatibility.
2Reliability
If polymer drug delivery systems are used, then drug delivery control is improved, but a disconnect between polymer degradation time and drug release period occurs
Solution Approach 1:
The patent incorporates the drug directly into the polymer backbone structure during synthesis, creating a prodrug where the drug is pre-positioned for release. The ester bonds are designed to hydrolyze at predictable rates, ensuring the drug release profile matches the polymer degradation timeline, eliminating the disconnect between degradation and release.
Solution Approach 2:
The patent establishes a continuous relationship between polymer degradation and drug release through covalent bonding. As the poly(β-amino ester) backbone degrades continuously via ester bond hydrolysis, the drug is continuously released in proportion, maintaining consistent therapeutic levels without interruption or mismatch between degradation and release phases.
3Reliability
If polymer drug delivery systems are used, then consistent drug levels are maintained, but initial burst release occurs
Solution Approach 1:
The patent incorporates the drug covalently into the polymer backbone before administration, preventing any initial free drug presence. The drug is held in a stable, bonded state and released only as the polymer degrades over time, eliminating the initial burst release that occurs when pre-formed drug-polymer complexes are used.
Solution Approach 2:
The patent creates a continuous, progressive release mechanism where drug release occurs steadily as the polymer degrades. The covalent bonding ensures drug is released in continuous proportion to polymer breakdown, maintaining stable drug levels from the start of therapy rather than experiencing an initial burst followed by depletion.
4Reliability
If controlled polymer drug release systems are used, then therapeutic benefit is improved, but cost increases significantly
Solution Approach 1:
The patent uses inexpensive, naturally abundant materials (amino acids and sugars) to create biodegradable poly(β-amino ester) polymers that break down completely in the body. This replaces expensive, persistent synthetic polymers with cheap, disposable-like materials that are metabolized and eliminated, reducing manufacturing cost while maintaining therapeutic benefit through controlled release.
Solution Approach 2:
The patent changes the material composition parameters to use commodity chemical building blocks (amino acids, sugars) rather than specialized synthetic polymers. This parameter change dramatically reduces material cost while the controlled release mechanism is achieved through the inherent chemistry of the natural materials, maintaining therapeutic benefit at lower cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel prodrug system provides a biocompatible, biodegradable, and cost-effective means of delivering drugs with a consistent release profile, reducing the risk of under- or over-dosing and simplifying administration.
Implementation Method 1
cross-linking said at least one polymer prodrug in the presence of a free radical initiator in a reaction mixture, thereby making the hydrogel prodrug
Data Source
AI summary
Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.